MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: Academy Military Medical Science, China; Guangdong General Hospital; Guangdong Provincial People's Hospital; Guangzhou First Municipal People’s Hospital; Guangzhou First People's Hospital; Guangzhou General Hospital of Guangzhou Military Command; Huazhong University of Science and Technology; Peking University People's Hospital; Southern Medical University, China; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-sen University; Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Antibodies; Antibodies, Monoclonal; Calcineurin Inhibitors; Immunoglobulins

Criteria

Inclusion Criteria:

• age of 14-65 years

• steroid-resistant aGVHD

• subjects (or their legally acceptable representatives) must have signed an informed consent document

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Patients with any conditions not suitable for the trial (investigators' decision)